Congressional Efforts: Proposed Laws to Address Drug Shortages in the 119th Congress

Imagine walking into your pharmacy for a life-saving medication, only to be told it’s out of stock. This isn’t a rare glitch; it is a systemic crisis affecting millions of Americans. As of late 2025, nearly 300 drugs were on the shortage list, with almost half classified as critical for treating life-threatening conditions. The frustration is palpable among patients and providers alike. But what is Washington doing about it? In the 119th Congress (the legislative session running from 2025 to 2026), lawmakers have introduced specific bills aimed at fixing these supply chain breaks. However, progress has been stalled by political gridlock and government shutdowns.

The Core Problem: Why Drugs Are Disappearing

To understand the proposed laws, you first need to grasp why shortages happen. It is rarely just one factor. According to data from the Association for Accessible Medicines, manufacturing delays caused 63% of drug shortages in October 2025. When a factory slows down or shuts for maintenance, the ripple effect hits pharmacies weeks later. Another major issue is lack of visibility. Manufacturers often do not tell the Food and Drug Administration (FDA) until it is too late that they cannot meet demand. By the time the FDA posts an alert, hospitals are already scrambling for alternatives.

This opacity creates a dangerous game of telephone between suppliers, distributors, and prescribers. Patients suffer because doctors cannot prescribe medications they know will not be available. The current system relies heavily on reactive measures rather than proactive planning. That is exactly what new legislation aims to change.

S.2665: The Drug Shortage Prevention Act of 2025

The most direct response to pharmaceutical scarcity is the Drug Shortage Prevention Act of 2025 (S.2665). Introduced by Senator Amy Klobuchar (D-MN) on August 1, 2025, this bill targets the root cause of surprise shortages: poor communication. The core mechanism is simple but powerful. It amends the Federal Food, Drug, and Cosmetic Act to require manufacturers of critical drugs to notify the FDA when they anticipate increased demand or potential supply issues.

Think of it like a weather forecast for medicine. Instead of waiting for the storm to hit, manufacturers would provide early warnings. This allows the FDA and healthcare providers to prepare inventory, find alternative sources, or adjust treatment plans before stocks run dry. The bill specifically focuses on "critical drugs," though the exact definition remains under review by the Senate Committee on Health, Education, Labor, and Pensions.

The bill was referred to committee immediately upon introduction. As of November 2025, it remained at the committee stage. No further action had been recorded due to the ongoing legislative paralysis. While the concept is sound, implementation details such as timelines and penalties were not fully disclosed in public records, leaving some uncertainty about how strictly it would be enforced.

H.R.1160: Addressing the Provider Shortage

Drug shortages are only half the battle. Even if every pill were available, patients still face barriers if there are no doctors to prescribe them. Enter the Health Care Provider Shortage Minimization Act of 2025 (H.R.1160). Introduced in the House of Representatives during the same session, this bill tackles the workforce crisis. The American Association of Medical Colleges projects a shortage of 124,000 physicians by 2034. Currently, 122 million Americans live in primary care Health Professional Shortage Areas.

Unlike S.2665, detailed summaries of H.R.1160 were scarce in early congressional records. However, its title and context suggest a focus on workforce development incentives, loan forgiveness programs, or expanded training slots. The goal is to get more providers into underserved areas where both drug access and medical expertise are lacking. Without enough hands on deck, even the best-supplied pharmacies cannot serve communities effectively.

The Shutdown Barrier: Why Progress Stalled

If these bills sound promising, why haven’t they passed? The answer lies in the unprecedented government shutdown that began on October 1, 2025. This event marked the longest shutdown in U.S. history, lasting through November 2025. During a shutdown, non-essential federal operations halt. For healthcare legislation, this is catastrophic.

The FDA lost approximately 800,000 furloughed workers across federal agencies, including staff responsible for monitoring drug supplies. The Drug Shortage Portal, a critical tool for tracking availability, saw degraded functionality due to lack of maintenance. How can we implement better notification systems when the agency tasked with receiving them is understaffed? Furthermore, the Congressional Budget Office estimated that effective oversight for S.2665 would require $45 million annually. With a $1.74 trillion deficit and billions cut from other programs, finding new funding became politically toxic.

Senate Republicans proposed a continuing resolution extending funding through January 30, 2026, but it contained no provisions addressing drug or provider shortages. This omission highlights a harsh reality: public health crises often lose out to partisan budget battles. Congressman Don Beyer criticized this approach, noting the marginalization of shortage issues despite their severity.

Impact on Hospitals and Patients

The human cost of this legislative limbo is high. A survey by the American Hospital Association found that 98% of hospitals experienced at least one critical drug shortage in Q3 2025. Physicians reported similar frustrations. An AMA survey showed that 87% of doctors dealt with shortages affecting patient care, yet only 12% knew about H.R.1160. There is a massive disconnect between policymakers and frontline providers.

Patient forums reflect this anger. On Reddit’s r/healthpolicy, users expressed frustration that Congress ignores worsening crises while focusing on procedural disputes. One thread noted that patients are forced to switch medications frequently, leading to adverse reactions and delayed treatments. These stories underscore why timely passage of S.2665 and H.R.1160 matters-not just for statistics, but for individual lives.

What Happens Next?

As the 119th Congress nears its end, both bills face probable expiration. If the shutdown is not resolved by January 2026, these efforts may die without becoming law. The 120th Congress will convene in January 2027, potentially offering a fresh start. However, restarting the process means losing valuable time. Every month without reform sees more patients affected.

Stakeholders must stay engaged. Advocacy groups, professional associations, and citizens can pressure representatives to prioritize health security over political maneuvering. Supporting transparency initiatives like the Stop Secret Spending Act (S.872) could also indirectly help by improving fiscal oversight, though it does not directly solve shortages.